{"id":"na-831","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NA-831 works by inhibiting the SGLT2 receptor, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine, resulting in reduced blood glucose levels. By targeting this receptor, NA-831 aims to improve glycemic control in patients with diabetes.","oneSentence":"NA-831 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:19.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04452565","phase":"PHASE2, PHASE3","title":"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2022-06-15","conditions":"Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":525},{"nctId":"NCT04540185","phase":"PHASE3","title":"A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2020-11-01","conditions":"Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection","enrollment":3600},{"nctId":"NCT04480333","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2020-09-15","conditions":"Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome","enrollment":45},{"nctId":"NCT03538522","phase":"PHASE2","title":"A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831","status":"COMPLETED","sponsor":"Biomed Industries, Inc.","startDate":"2018-09-15","conditions":"Mild Cognitive Impairment, Alzheimer Disease, Alzheimer Dementia","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NA-81 is a neuroprotective drug"],"phase":"phase_3","status":"active","brandName":"NA-831","genericName":"NA-831","companyName":"Biomed Industries, Inc.","companyId":"biomed-industries-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NA-831 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}